title: Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis.
abstract: In patients with rheumatoid arthritis (RA) a decrease in the terminal galactose content of N-linked glycans of the Fc region of agalactosyl immunoglobulin G (IgG) (G0) occurs. The aim of this study was to evaluate, for the first time, the effect of infliximab, a new monoclonal antibody for the treatment of RA, on this phenomenon. A total of 19 patients with active RA were treated with intravenous infliximab (3 mg/kg) in combination with methotrexate (MTX) (10-20 mg). IgG was purified from their serum by caprylic acid. Analysis of IgG glycosylation was performed by lectin blotting/immunoblotting and enzyme linked lectin assay (ELLA)/enzyme linked immunosorbent assay (ELISA) using the Griffonia (bandeiraea) simplicifolia lectin II and protein-A/alkaline phosphatase. The purity of IgG samples obtained was higher than 90%. The sensitivity of the lectin/immunoblotting method was of about 0.25 microg of IgG. The inter- and intraassay coefficients of variation (CV) were 1.3% and 9.0% for lectin blotting, and 4.6% and 8.3% for immunoblotting, respectively. The sensitivity of the ELLA/ELISA approach was 0.025 microg/microL and the inter- and intraassay CV were 6.2% and 7.7% for ELLA, and 5.1% and 14.1% for ELISA, respectively. A good linear correlation (r2=0.18, P<0.05) was obtained between the two different experimental approaches. A decrease of G0 was observed in patients who clinically improved (according to the American College of Rheumatology criteria) following the pharmacological treatment. Our data indicate that infliximab can reduce the concentration of G0 in patients with active RA.
authors.affiliation: Department of Human Physiology and Pharmacology Vittorio Erspamer, University of Rome La Sapienza, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Croce
authors.forename: O
authors.initials: O
authors.lastname: Firuzi
authors.forename: F
authors.initials: F
authors.lastname: Altieri
authors.forename: M
authors.initials: M
authors.lastname: Eufemi
authors.forename: R
authors.initials: R
authors.lastname: Agostino
authors.forename: R
authors.initials: R
authors.lastname: Priori
authors.forename: M
authors.initials: M
authors.lastname: Bombardieri
authors.forename: C
authors.initials: C
authors.lastname: Alessandri
authors.forename: G
authors.initials: G
authors.lastname: Valesini
authors.forename: L
authors.initials: L
authors.lastname: Saso
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002210:Caprylates / Q000737:chemistry; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D000069285:Infliximab; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D002210:Caprylates; D007074:Immunoglobulin G; C064155:agalactosyl IGG; D000069285:Infliximab; C031492:octanoic acid